Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1974 1
1975 1
1977 1
1978 1
1980 1
1982 1
1990 1
1991 1
1994 1
1995 3
2000 1
2002 1
2003 1
2005 1
2006 1
2009 2
2010 1
2012 3
2013 3
2014 5
2015 10
2016 9
2017 6
2018 12
2019 17
2020 8
2021 18
2022 13
2023 13
2024 20

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

138 results

Results by year

Filters applied: . Clear all
Page 1
[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial.
Hofman MS, Emmett L, Sandhu S, Iravani A, Joshua AM, Goh JC, Pattison DA, Tan TH, Kirkwood ID, Ng S, Francis RJ, Gedye C, Rutherford NK, Weickhardt A, Scott AM, Lee ST, Kwan EM, Azad AA, Ramdave S, Redfern AD, Macdonald W, Guminski A, Hsiao E, Chua W, Lin P, Zhang AY, McJannett MM, Stockler MR, Violet JA, Williams SG, Martin AJ, Davis ID; TheraP Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group. Hofman MS, et al. Among authors: redfern ad. Lancet. 2021 Feb 27;397(10276):797-804. doi: 10.1016/S0140-6736(21)00237-3. Epub 2021 Feb 11. Lancet. 2021. PMID: 33581798 Clinical Trial.
Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial.
Hofman MS, Emmett L, Sandhu S, Iravani A, Buteau JP, Joshua AM, Goh JC, Pattison DA, Tan TH, Kirkwood ID, Ng S, Francis RJ, Gedye C, Rutherford NK, Weickhardt A, Scott AM, Lee ST, Kwan EM, Azad AA, Ramdave S, Redfern AD, Macdonald W, Guminski A, Hsiao E, Chua W, Lin P, Zhang AY, Stockler MR, Williams SG, Martin AJ, Davis ID; TheraP Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group. Hofman MS, et al. Among authors: redfern ad. Lancet Oncol. 2024 Jan;25(1):99-107. doi: 10.1016/S1470-2045(23)00529-6. Epub 2023 Nov 30. Lancet Oncol. 2024. PMID: 38043558 Clinical Trial.
Editorial: Changing of the guard.
Verstraten FAJ, Meese TS, Redfern AS, Mamassian P. Verstraten FAJ, et al. Among authors: redfern as. Perception. 2024 Oct;53(10):671-673. doi: 10.1177/03010066241284787. Epub 2024 Sep 12. Perception. 2024. PMID: 39267412 Free PMC article. No abstract available.
[177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial.
Emmett L, Subramaniam S, Crumbaker M, Nguyen A, Joshua AM, Weickhardt A, Lee ST, Ng S, Francis RJ, Goh JC, Pattison DA, Tan TH, Kirkwood ID, Gedye C, Rutherford NK, Sandhu S, Kumar AR, Pook D, Ramdave S, Nadebaum DP, Voskoboynik M, Redfern AD, Macdonald W, Krieger L, Schembri G, Chua W, Lin P, Horvath L, Bastick P, Butler P, Zhang AY, Yip S, Thomas H, Langford A, Hofman MS, McJannett M, Martin AJ, Stockler MR, Davis ID; ENZA-p Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group. Emmett L, et al. Among authors: redfern ad. Lancet Oncol. 2024 May;25(5):563-571. doi: 10.1016/S1470-2045(24)00135-9. Epub 2024 Apr 12. Lancet Oncol. 2024. PMID: 38621400 Clinical Trial.
Seasonal variations in cardiovascular disease.
Stewart S, Keates AK, Redfern A, McMurray JJV. Stewart S, et al. Among authors: redfern a. Nat Rev Cardiol. 2017 Nov;14(11):654-664. doi: 10.1038/nrcardio.2017.76. Epub 2017 May 18. Nat Rev Cardiol. 2017. PMID: 28518176 Review.
Heart failure following oncological treatment.
Marangou J, Redfern A, Haddad T, Rankin JM, Dwivedi G. Marangou J, et al. Among authors: redfern a. Curr Opin Cardiol. 2018 Mar;33(2):237-244. doi: 10.1097/HCO.0000000000000488. Curr Opin Cardiol. 2018. PMID: 29251671 Review.
Synthetic Epigenetic Reprogramming of Mesenchymal to Epithelial States Using the CRISPR/dCas9 Platform in Triple Negative Breast Cancer.
Waryah C, Cursons J, Foroutan M, Pflueger C, Wang E, Molania R, Woodward E, Sorolla A, Wallis C, Moses C, Glas I, Magalhães L, Thompson EW, Fearnley LG, Chaffer CL, Davis M, Papenfuss AT, Redfern A, Lister R, Esteller M, Blancafort P. Waryah C, et al. Among authors: redfern a. Adv Sci (Weinh). 2023 Aug;10(22):e2301802. doi: 10.1002/advs.202301802. Epub 2023 May 22. Adv Sci (Weinh). 2023. PMID: 37217832 Free PMC article.
Hypoxia as a signal for prison breakout in cancer.
Redfern A, Agarwal V, Thompson EW. Redfern A, et al. Curr Opin Clin Nutr Metab Care. 2019 Jul;22(4):250-263. doi: 10.1097/MCO.0000000000000577. Curr Opin Clin Nutr Metab Care. 2019. PMID: 31116106 Review.
138 results